Literature DB >> 7748535

Live tularemia vaccine but not proteins purified from Francisella tularensis can confer protection against lethal Listeria infection in mice.

Y F Belyi1, V V Petrosov, I S Tartakovskii, Y G Suchkov.   

Abstract

Immunization of Balb/c mice with Francisella tularensis vaccine strain 15/10 conferred significant protection against subsequent listerial infection. Since immunostimulatory activities could apparently be relevant to surface components of the bacterium, a technique for purification of cell wall proteins was developed. The scheme designed consisted of Triton X-100 extraction with subsequent FPLC chromatography steps, and resulted in the isolation of homogeneous proteins with molecular masses of 54 kDa (pI = 6.7) and 82 kDa (pI = 5.3), and partially purified 50, 85 and 100 kDa components. It was shown that immunization with isolated proteins failed to protect mice against lethal Listeria monocytogenes infection. Possible reasons for failure are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7748535

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  4 in total

1.  Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis.

Authors:  Qingmei Jia; Bai-Yu Lee; Daniel L Clemens; Richard A Bowen; Marcus A Horwitz
Journal:  Vaccine       Date:  2009-01-04       Impact factor: 3.641

2.  Nonspecific early protective immunity in Francisella and Listeria infections can be dependent on lymphocytes.

Authors:  K L Elkins; A T MacIntyre; T R Rhinehart-Jones
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

3.  Preclinical testing of a vaccine candidate against tularemia.

Authors:  Ragavan Varadharajan Suresh; Zhuo Ma; Raju Sunagar; Vivek Bhatty; Sukalyani Banik; Sally V Catlett; Edmund J Gosselin; Meenakshi Malik; Chandra Shekhar Bakshi
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

4.  An Improved Tobacco Mosaic Virus (TMV)-Conjugated Multiantigen Subunit Vaccine Against Respiratory Tularemia.

Authors:  Ahd A Mansour; Sukalyani Banik; Ragavan V Suresh; Hardeep Kaur; Meenakshi Malik; Alison A McCormick; Chandra S Bakshi
Journal:  Front Microbiol       Date:  2018-06-05       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.